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Abstract
The past ten years parallels have been drawn between the biology of cancer and pulmonary fibrosis.
The unremitting recruitment and maintenance of the altered fibroblast phenotype with generation
and proliferation of immortal myofibroblasts is reminiscent with the transformation of cancer cells.
A hallmark of tumorigenesis is the production of new blood vessels to facilitate tumor growth and
mediate organ-specific metastases. On the other hand several chronic fibroproliferative disorders
including fibrotic lung diseases are associated with aberrant angiogenesis. Angiogenesis, the process
of new blood vessel formation is under strict regulation determined by a dual, yet opposing balance
of angiogenic and angiostatic factors that promote or inhibit neovascularization, respectively. While
numerous studies have examined so far the interplay between aberrant vascular and matrix
remodeling the relative role of angiogenesis in the initiation and/or progression of the fibrotic
cascade still remains elusive and controversial. The current article reviews data concerning the
pathogenetic role of angiogenesis in the most prevalent and studied members of ILD disease-group
such as IIPs and sarcoidosis, presents some of the future perspectives and formulates questions for
potential further research.
Introduction
The interstitial lung diseases (ILDs) are a heterogeneous
group of diffuse parenchymal lung diseases comprising
different clinical and histopathological entities that have
been broadly classified into several categories [1,2]
including sarcoidosis and idiopathic interstitial pneumo-
nias (IIPs). The latter have been recently classified into
seven different disease-members [3-8]. The most impor-
tant and frequent of these conditions are idiopathic pul-
monary fibrosis (IPF) with the histopathologic pattern of
usual interstitial pneumonia (UIP), non-specific intersti-
tial pneumonia (NSIP) and cryptogenic organizing pneu-
monia (COP). Their aetiology has remained elusive and
the molecular mechanisms driving their pathogenesis are
poorly understood. Recent theories implicate recurrent
injurious exposure, imbalance that shifts Th1/Th2 equi-
librium towards Th2 immunity and angiogenesis in the
pathogenesis of pulmonary fibrosis, both in human and
experimental studies [9]. The Th1/Th2 pathway and ang-
iogenesis have been recently suggested to play pivotal role
in the immunopathogenesis of sarcoidosis contributing
to the formation of granuloma, the main histopathologic
feature of the disease [10].
The scope of this review article is to summarize the current
state of knowledge regarding angiogenic and angiostatic
activity in the most important and prevalent members of
ILD disease-group such as IIPs and sarcoidosis, discuss its
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pathogenetic role and present some of the future perspec-
tives and limitations based on authors' assessment or orig-
inated from the statements of original authors.
1. Definitions
Angiogenesis is the process of new capillary blood vessels
growth and is instrumental under both physiologic and
pathologic conditions. Physiologic conditions include
embryogenesis, growth, tissue repair after injury and the
female reproductive cycle whereas pathologic angiogen-
esis can occur in chronic inflammatory and fibroprolifer-
ative disorders and tumorigenesis of cancer. Angiogenesis
is similar to but distinct from vasculogenesis which
describes the de novo formation of blood vessels from
angioblasts or endothelial progenitor cells, process that
mostly occurs during embryogenesis [11]. On the other
hand, angiogenesis describes the sprouting of new vessels
from pre-existing vasculature which can occur both in
embryonic and adult life. The regulation of angiogenesis
is determined by a dual, yet opposing balance of ang-
iogenic and angiostatic factors that promote or inhibit
neovascularization, respectively.
2. Angiogenic mediators in interstitial lung diseases (Table 
1)
Molecules that originally promote angiogenesis include
members of the CXC chemokine family, characteristically
heparin binding proteins which on structural level have
four highly conserved cysteine amino acid residues, with
the first two cysteines separated by one nonconserved
amino acid residue. CXC chemokines display unique
diverse roles in the regulation of angiogenesis resulting
from dissimilarity in structure. Therefore, members that
contain in the NH2-terminus a three amino-acid motif
(ELR) such as IL-8/CXCL8, epithelial neutrophil activat-
ing protein (ENA)-78/CXCL5, growth-related genes
(GROs, a, β, γ/CXCL1, 2, 3), granulocyte chemotactic pro-
tein (GCP)-2/CXCL6 and neutrophil activating protein
(NAP)-2/CXCL7, originally promote angiogenesis
[11,12]. There are two candidate CXC chemokine recep-
tors that mediate this effect: CXCR1 and CXCR2 [11,12].
Another crucial promoter of angiogenesis is vascular
endothelial growth factor (VEGF) a dimorphic glycopro-
tein with multifunctional roles in both the development
of vasculature and the maintenance of vascular structure
and function [13,14]. Its expression is induced when most
cell types are subjected to hypoxia [15]. Finally, another
positive regulator of aberrant vascular remodeling in pul-
monary fibrosis is basic fibroblast growth factor (bFGF)
Table 1: List of studied angiogenic and angiostatic mediators in ILDs
Angiogenic mediators
CXC chemokines containing the ELR motif
• GRO-a/CXCL1
• GRO-b/CXCL2
• GRO-γ/CXCL3
• ENA-78/CXCL5
• GCP-2/CXCL6
• NAP-2/CXCL7
• IL-8/CXCL8
Growth Factors
• VEGF
• bFGF
Angiostatic mediators
CXC chemokines that lack the ELR motif
• PF-4/CXCL4
• MIG/CXCL9
• IP-10/CXCL10
• ITAC/CXCL11
• CXCL14
Growth Factors
• PEDF
Abbreviations: bFGF: basic fibroblast growth factor, GCP: Granulocyte chemotactic protein, GRO: Growth related genes, IP-10:IFN-γ-inducible -
protein 10, ITAC: IFN-γ-inducible T-cell a chemoattractant, MIG: Monocyte Induced by interferon gamma-protein, NAP: Neutrophil activating 
protein, PEDF: Pigment epithelium growth factor, PF: Platelet factor,, VEGF: Vascular growth factorRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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which has been shown originally to stimulate the prolifer-
ation of cells of mesodermal origin, including fibroblasts
[16]. In addition, it has been shown that inappropriate
expression of bFGF can result in tumor production
through promotion of uncontrolled cell proliferation and
aberrant angiogenesis [17-19].
3. Angiostatic mediators in interstitial lung diseases (Table 
1)
By contrast, other members of the CXC chemokine family
that do not contain the angiogenic ELR motif (ELR-)
behave as potent inhibitors of angiogenesis. Platelet fac-
tor-4 (PF-4)/CXCL4 was the first chemokine described to
inhibit aberrant angiogenesis. Furthermore, the angi-
ostatic ELR- members of the CXC chemokine family
include the interferon (IFN)-γ inducible protein (IP)-10/
CXCL10, monokine induced by IFN-γ (MIG)-2 and IFN-γ-
inducible T-cell a chemoattractant (ITAC)/CXCL11
[11,12]. The latter inhibit angiogenesis via interaction
with the specific CXC chemokine receptor CXCR3 which
is expressed in Th1 and natural killer (NK) cells. Addition-
ally, pigment epithelium-derived factor (PEDF) is an
inhibitor of new vessel formation, first described in retinal
pigmented epithelial cells during diabetic retinopathy and
then in young proliferating fibroblasts [20]. Its expression
in retinal cell lines has been documented to be directly
regulated by VEGF [21]. PEDF angiostatic activities are
specific for new developing vessels and its expression has
been detected in kidney, pancreas, prostate, pleura, testes,
bone, within peripheral blood cells and recently in lung
[21].
4. Pathogenetic pathways during aberrant angiogenesis
Several transcription factors play instrumental role in pro-
moting angiogenesis and sensing the environmental cues
that drive this process. Strieter et al. [22] identified two
transcription factors that stand out and appreciated the
"master switches" that control aberrant angiogenesis.
These are nuclear factor-κB (NF-κB) and hypoxia induci-
ble factor-1a (HIF-1a). Both factors are under strict regula-
tion. NF-κB plays an essential role as a "master switch" in
the transactivation of angiogenic CXC chemokines as
shown in detail for CXCL8 (Figure 1). Generation of reac-
tive oxygen species activates NF-κB and sets in motion a
process that releases NF-κB in the cytoplasm and leads to
its translocation into the nucleus where it binds with the
promoters of angiogenic CXC chemokines resulting to the
activation of target genes [23]. In addition, it has been
shown that VEGF promotes the expression of angiogenic
chemokines (i.e CXCL8) from endothelial cells in an
autocrine and paracrine way [13] (Figure 1). On the other
hand, HIF-1a serves as a critical transcription factor for
cellular and systemic oxygen homeostasis. Under hypoxic
conditions HIF-1a is subsequent to activation and translo-
cation into the nucleus. There it dimerizes with HIF-1b
and the heterodimer recognizes the hypoxia response ele-
ment found in the promoter region of several target genes
(i.e VEGF) resulting to gene expression (Figure 1) [24,25].
Angiogenesis in Interstitial Lung Diseases
a. Angiogenesis in Idiopathic Interstitial Pneumonias 
(Tables 2, 3, 4)
The past ten years parallels have been drawn between the
biology of cancer and pulmonary fibrosis. The unremit-
ting recruitment and maintenance of the altered fibroblast
phenotype with generation and proliferation of immortal
myofibroblasts is reminiscent with the transformation of
cancer cells [26-37]. A hallmark of tumorigenesis is the
production of new blood vessels to facilitate tumor
growth. A number of novel treatments targeting angiogen-
esis are in varying stages of clinical development for can-
cer [38]. On the other hand several chronic
fibroproliferative disorders including IIPs are associated
Schematic representation of the two major pathogenetic  pathways regulating angiogenesis in pulmonary fibrosis Figure 1
Schematic representation of the two major pathogenetic 
pathways regulating angiogenesis in pulmonary fibrosis. 
Under normal oxygen conditions HIF-1a is subject to ubiqui-
tination and proteasomal degradation. Under hypoxic condi-
tions, its ubiquitination is inhibited and HIF-1a is activated 
through the same kinase pathways with NF-κB and translo-
cates to the nucleus. There it dimerizes with HIF-1b and the 
heterodimer recognizes specific allelic sequences located 
within the hypoxia response element found in the promoter 
region of several target genes (i.e VEGF). In addition, VEGF 
may directly promote the expression of angiogenic chemok-
ines (i.e CXCL8) from endothelial cells in an autocrine and 
paracrine way. Generation of reactive oxygen species and 
activation of kinase pathogenetic pathways converges and 
activates NF-κB and sets in motion a process that releases 
NF-κB in the cytoplasm and leads to its translocation into 
the nucleus. There, all the promoters of angiogenic CXC 
chemokines contain a putative cis-element that recognizes 
and binds the transcriptional factor resulting to the activation 
of target genes and ultimately to protein synthesis.
HIF-1a Ubiquitination Degradation
Hypoxia
HIF-1b
HRE VEGF-gene
promoter
mRNA Protein
Angiogenesis
cytoplasm
nucleus
NF-κB
Ubiquitination Degradation
ROS
cytoplasm
nucleus ELR+ CXC chemokines-gene
mRNA Protein
Abbreviations: HIF: Hypoxia inducible factor, HRE: Hypoxia response elements, VEGF: Vascular endothelial 
growth  factor, ROS: Reactive oxygen species, Respiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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with aberrant angiogenesis [39]. In parallel with the biol-
ogy of the fibroblast proliferation and deposition of ECM
in IIPs, a considerable number of studies have examined
the role of angiogenesis/vascular remodeling in wound
healing and its contribution to the fibroproliferation and
ECM deposition characterizing these disorders [39].
i. Human studies (Tables 2 and 3)
There is increasing evidence supporting the notion that
vascular remodeling in fibroproliferative disorders
appears to be regulated by an imbalance between ang-
iogenic and angiostatic factors. Seminal observation
implicating angiogenic activity as an important aspect of
progressive fibrosis was originally made by Turner-War-
wick in 1963, when she demonstrated the presence of
anastomoses between the systemic and pulmonary micro-
vasculature in lungs of patients with IPF [40]. Despite
these data suggesting a potential role of neovasculariza-
tion in fibrogenesis, the exact contribution of aberrant
vascular remodeling to the progression of fibrosis has
been, so far, largely ignored. On the other hand, the
pathology of IPF demonstrates temporal and regional het-
erogeneity and presents with distinct pathogenetic com-
ponents compared to other IIPs that may explain major
discrepancies in terms of clinical course, prognosis and
responsiveness to treatment. On the basis of this concep-
tion, the last decade, a number of reports addressed
intriguing questions arising from the above data. These
include the following: 1) Is the primary vascular abnor-
mality a lack or an excess of neovascularization and con-
sequently what is the role of angiogenesis in the fibrotic
process? 2) Is there any association of vascular remodeling
with the histopathologic pattern of the IIP? or 3) any cor-
relation with parameters of disease severity?
Table 2: Human studies investigating angiogenic and angiostatic parameters in patients with idiopathic interstitial pneumonias (1997–
2003)
Investigator (year) Tissue samples 
Sample size
IIP Studied 
Parameters
Summary Limitations
Keane et al. 41(1997) Lung specimens/50 
patients/54 controls
IPF CXCL8, 10 Increased levels of 
CXCL8,10 that favor 
angiogenesis
Incomplete analysis of 
the angiogenic 
network / In vivo 
micropocket assay
Lappi-Blanco et al.53 
(1999)
Lung specimens/19 
patients
IPF-COP VWF, CD34+ Small sample size / 
Lack of knowledge 
regarding factors 
responsible for 
vascular heterogeneity
Meyer et al. 43 (2000) BALF samples/32 
patients/66 controls
IPF-CF-SARCO VEGF Decreased VEGF 
levels in IPF patients
Small number of 
patients /  No 
correlation between 
serum and BALF 
levels / No correlation 
with clinical 
parameters of disease 
severity
Keane et al. 42 (2001) Lung specimens/91 
patients/78 controls
IPF CXCL5 Increased CXCL5 
levels in IPF patients
Incomplete analysis of 
the angiogenic 
network
Lappi-Blanco et al. 
54(2002)
Lung specimens/19 
patients
IPF-COP VEGF, bFGF Increased VEGF and 
bFGF levels in MB 
compared to FF
Small sample size / 
Lack of knowledge 
regarding angiostatic 
regulators
Koyama et al. 44 
(2002)
BALF samples/49 
patients/27controls
IPF-PF/CTD-SARCO VEGF Decreased VEGF 
levels in IPF patients
High variability 
between serum and 
BALF levels in health 
and disease
Renzoni et al. 45 
(2003)
Lung specimens/17 
patients/12 controls
CFA-SSc Vascular density and 
distribution
Abnormal vascular 
distribution in areas 
proximal to gas 
exchange / 
Phenotypically altered 
vessels
Morphometric study 
not suitable to identify 
the role of 
angiogenesis in 
hypoxemia
Abbreviations: BALF: Bronchoalveolar lavage fluid, bFGF: basic fibroblast growth factor, CF: Cystic fibrosis, CFA: Cryptogenic fibrosing alveolitis, 
COP: Cryptogenic organizing pneumonia, FF: Fibroblastic foci, IFN-γ: Interferon gamma, IIPs: Idiopathic Interstitial Pneumonias, IPF: Idiopathic 
pulmonary fibrosis, MB: Masson bodies, NSIP: Non-specific interstitial pneumonia, PF-CTD: Pulmonary fibrosis associated with a connective tissue 
disease, SARCO: Sarcoidosis, VEGF: Vascular endothelial growth factorRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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1) Is there too much or too little?
Keane and colleagues were the first addressing this crucial
issue. They demonstrated increased angiogenic activity in
a large number of IPF lung specimens [41,42] and specu-
lated that there it may be an opposing balance of ang-
iogenic (CXCL8, CXCL5) and angiostatic factors
(CXCL10) that favors angiogenesis [41,42]. However,
other reports made the role of angiogenesis in IPF contro-
versial. Meyer et al. [43] and Koyama et al. [44] docu-
mented depressed VEGF BALF levels in IPF patients
compared to a variety of diffuse parenchymal lung dis-
eases or healthy controls. However, an extremely high var-
iability of serum and BALF VEGF levels in health and
disease has been reported, which is provoked by numer-
ous factors. These include epithelial cell apoptosis, cellu-
lar injury, proteolytic degradation due to smoking and
aging [44].
Original attempt to prove an association between abnor-
mal vasculature and regional heterogeneity characterizing
IPF was performed by Renzoni and coworkers [45].
Fueled by previous studies showing marked decrease of
interstitial vascularity in areas of extensive fibrosis
[46,47], authors reported clusters of phenotypically
Table 3: Human studies investigating angiogenic and angiostatic parameters in patients with idiopathic interstitial pneumonias (2004–
2005)
Investigator (year) Tissue samples 
Sample size
IIP Studied 
Parameters
Summary Limitations
Ebina et al. 48 (2004) Lung specimens/7 
patients/3 controls
IPF Vascular density 
CD34+, VWF, 
CXCL8, VEGF
Heterogeneous 
increase in CD34+ 
alveolar capillaries  / 
Morphologically 
altered vessels
Small sample size / 
Potential bias vascular 
density
Simler et al. 56 (2004) Serum samples/49 
patients
IPF-NSIP-DIP VEGF, CXCL8, ET1 Correlation of 
angiogenic cytokines 
with functional and 
radiological markers 
of disease severity
Heterogeneous group 
of IIPs / Patients not 
age and sex matched 
with controls / Lack of 
serial radiological data 
/ Limited number of 
patients
Strieter et al. 58 (2004) BALF-serum samples/
32 patients
IPF CXCL11 Upregulation of 
CXCL11 levels in IPF 
patients after 
treatment with IFN-γ
No correlation with 
parameters of disease 
progression p values 
were not adjusted for 
multiplicity
Cosgrove et al. 50 
(2004)
Lung specimens/15 
patients/12 controls
IPF-COP PEDF-VEGF Elevated PEDF and 
decreased VEGF 
levels within the FF. 
Increased VEGF levels 
within MB
In vitro angiogenic 
assay is less robust 
than the in vivo one  / 
Small sample size
Nakayama et al. 55 
(2005)
BALF samples/27 
patients/12 controls
IPF-NSIP CXCL5, 10 Increased levels of 
CXCL5 and 
decreased levels of 
CXCL10 in patients 
with IPF compared to 
NSIP
Discrepancies 
between BALF and 
serological data  / 
Limited number of 
patients
Belperio et al. 52 
(2005)
Lung specimens/BALF 
samples/68 patients/
47 controls
BOS CXCL1, 3, 5, 7, 8 
CXCR2
Increased levels of 
CXCR2/CXCR2 
ligands in lung biopsy 
and BALF samples 
from patients with 
BOS
Lack of evaluation of 
the angiostatic 
CXCR3/CXCR3 
ligands axis
Pignatti et al. 57 (2005) BALF and serum 
samples/47 patients/
10 controls
IPF-other ILDs CXCR3, CCR4 Correlation of 
elevated CXCR3 
levels with clinical 
parameters of disease 
severity in IPF patients
Lack of serial data in 
half of patients / No 
correlation with 
several parameters of 
disease severity / 
Discrepancies 
between serum and 
BALF levels
Abbreviations: BALF: Bronchoalveolar lavage fluid, COP: Cryptogenic organizing pneumonia, DIP: Desquamative Interstitial Pneumonia, FF: 
Fibroblastic foci, IFN-γ: Interferon gamma, IIPs: Idiopathic Interstitial Pneumonias, IPF: Idiopathic pulmonary fibrosis, MB: Masson bodies, NSIP: 
Non-specific interstitial pneumonia, PEDF: Pigment epithelial growth factor, VEGF: Vascular endothelial growth factor, VWF: Von Willebrand factorRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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altered vessels immediately adjacent to areas of active
fibrosis in patients with two different forms of fibrosing
alveolitis; IPF and fibrosing alveolitis associated with sys-
temic sclerosis. One of the most intriguing aspects of this
study was the demonstration of a substantial vascular
redistribution leading to a great proportion of vessels
removed from areas of gas exchange. This evidence was
further corroborated by Ebina et al [48]. Authors effec-
tively assessed by image analysis of dual immunostaining
(CD34+, von Willebrand factor-VWF) the interstitial vas-
cular density against the histologic severity of IPF. One of
the most remarkable ascertainments of this study was the
observation that both increased capillary density and vas-
cular regression are found in the same disease, according
to extent and severity of pulmonary fibrosis. Nevertheless,
these findings instead of answering the original question
generated novel hypotheses and gave birth to new dilem-
mas. What is the exact role of the increased angiogenic
activity found in the least fibrotic areas? Is it involved in
the fibrogenic process, is it a compensatory response or it
prevents it? Authors hypothesize that the aberrant vascu-
larity is compensatory to the vascular ablation seen in
areas of extensive fibrosis and may be beneficial for the
regeneration of the alveolar septa [49]. Nonetheless, fur-
ther studies are warranted to support this concept. With
this aim in mind, Cosgrove et al. [50] focused on the
fibroproliferative areas of COP and UIP and reported, in
agreement with previous reports [45,48], decreased vascu-
lar density within the fibroblastic foci. Scrutinizing for
potent anti-angiogenic molecules, authors found for the
first time a marked overexpression of a powerful angi-
ostatic mediator, PEDF, within the fibroblastic foci but
not in the Masson bodies. This finding was in contrary
with prior studies [41,42], in which angiogenesis was pro-
moted rather than suppressed. This disparity in the ang-
iogenic activity can be explained by the use of different
angiogenic assays or by the regional and temporal hetero-
geneity of IPF and can simply reflect pathological differ-
ences [51]. Finally, Belperio et al. [52] demonstrated
aberrant vascular remodeling in lung specimens of
patients with bronchiolitis obliterans pneumonia and
corroborated this observation in BALF samples where they
documented upregulated angiogenic activity.
2) Is there any association of angiogenic activity with the 
histopathologic pattern of the IIP?
Lappi-Blanco et al. addressed this crucial issue [53,54].
They were the first who performed a comparative study on
Table 4: Studies investigating tissue angiogenic and angiostatic parameters in experimental models of pulmonary fibrosis
Investigator (year) Model Studied Parameters Summary Limitations
Keane et al. 61(1999) BPF MIP-2 Increased levels of MIP-2 in 
BPF mice / Inhibition of 
angiogenesis and fibrosis 
with neutralizing Abs
Model not representative 
of IPF
Keane et al. 62(1999) BPF CXCL10 Decreased CXCL10 levels 
/ CXCL10 administration 
reduced BPF and 
angiogenic response
Model not representative 
of IPF
Jiang et al. 65 (2004) BPF CXCR3 Regulation of BPF by 
CXCR3
Model not representative 
of IPF /  Incomplete analysis 
of angiogenic network
Tager et al. 78 (2004) BPF CXCL10 Inhibition of BPF by 
CXCL10
Model not representative 
of IPF / Incomplete analysis 
of angiogenic network
Burdick et al. 63 (2005) BPF CXCL11 Systemic administration of 
CXCL11 inhibited BPF by 
altering aberrant vascular 
remodeling
Model not representative 
of IPF / Incomplete analysis 
of angiogenic network
Belperio et al. 52 (2005) Murine BOS CXCL1, 2, 3 CXCR2, 
VEGF
Increased CXCR2/CXCR2 
ligands' levels / Unchanged 
levels of VEGF / 
Neutralization of CXCR2 
attenuated angiogenesis 
and BOS
Model has heterotopic 
positioning and discounts 
influence of adjacent airway 
mucosa
Hamada et al. 64 (2005) BPF VEGF, sflt-1 Anti-VEGF gene therapy 
attenuates lung injury and 
fibrosis in BPF mice
Model not representative 
of IPF / Incomplete analysis 
of angiogenic network
Abbreviations: BPF: Bleomycin-induced pulmonary fibrosis, IPF: Idiopathic pulmonary fibrosis, VEGF: Vascular endothelial growth factorRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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the net angiogenic activity found in two different forms of
IIPs (UIP and COP) clinically and histologically distin-
guishable. A pronounced vascular remodeling in the
fibromyxoid lesions of COP compared to the fibroblastic
foci of UIP was reported [53]. In another study, same
group of authors demonstrated a distinct expression of
vascular growth factors (VEGF and bFGF) within the intra-
luminal connective tissue of UIP and COP [54]. Differen-
tial angiogenic profiles were also described by Cosgrove et
al. [50] who demonstrated increased angiostatic activity
within IPF lungs compared to COP tissue samples. In
addition, Nakayama et al. [55] documented a local pre-
dominance of angiogenic factors (CXCL5) in IPF patients
and angiostatic factors (CXCL10) in subjects with idio-
pathic NSIP.
3) Is there any correlation with parameters of disease severity?
There is a great lack of knowledge regarding this issue
which has been largely ignored. Renzoni et al. [45] were
the first addressing this issue. They performed a morpho-
metric analysis of the interstitial vascularity in two differ-
ent types of fibrosing alveolitis and stated an inverse
relation between alveolar-arterial oxygen gradient and the
proportion of vessels close to areas of gas exchange, evi-
dence that could explain the increased hypoxemia seen in
these patients. However, as it pointed out by the authors,
this study was morphometric and thus, unsuitable from
its origin to evaluate markers of disease severity and corre-
late them with immunologic parameters.
Towards this direction, Simler et al. [56] performed a
translational research of angiogenic cytokines (IL-8,
VEGF, endothelin-1) and associated them with clinical
parameters of disease progression over a 6-month period,
in patients with IIPs. Patients with progressive lung dis-
ease demonstrated higher plasma levels of all three
cytokines than non-progressors according to functional
and clinical criteria. In addition, a positive relationship
between the change in HRCT fibrosis score and the change
in plasma VEGF and a negative relationship between the
percentage change in forced vital capacity and the change
in plasma VEGF was noted. Potential limitations include
the analysis of a heterogeneous group of diseases, enrol-
ment of a limited number of subjects, not age and sex
matched with the controls and lack of serial radiological
data. However, investigators performed the first longitudi-
nal study in this field and identified potential prognosti-
cators of disease progressiveness, an area that has severely
hindered clinical research in ILDs.
A second attempt to correlate local and systemic expres-
sion of angiogenic mediators with clinical biomarkers of
disease severity and activity was recently published by Pig-
natti et al [57]. They investigated the role of CXCR3 com-
pared to CCR4 known to mediate Th2 response and
reported a predominance of a Th2 microenvironment in
IPF patients. An imbalance of the CXCR3/CCR4 expres-
sion in BALF T lymphocytes was well correlated with func-
tional and radiological parameters of disease severity,
speculating that these immunomodulators could function
as prognostic guides of the disease course.
Finally, Strieter et al. [58] recently published the only, so
far, study supporting the notion that mortality in IPF
patients could be potentially improved through the anti-
angiogenic properties of IFN-γ 1b supporting its therapeu-
tic utility. More prospective studies in well defined sub-
groups of IIPs are needed to strengthen this assertion and
assess the clinical utility of biomarkers of disease activity
[59].
ii. Experimental models (Table 4)
The vascular remodeling phenomenon has been also
described in the experimental model of bleomycin-
induced pulmonary fibrosis. The role of neovasculariza-
tion during the pathogenesis of experimental pulmonary
fibrosis was originally raised by Peao and coworkers [60].
In line with human data [40] investigators reported aber-
rant vascular remodeling in the peribronchial areas of the
lungs proximal to fibrotic regions and accompanied by
architectural distortions of the alveolar capillaries. While
these eloquent studies implicated the presence of angio-
genesis in the pathogenetic cascade of IPF, so far, there
have been no investigations to delineate factors that regu-
late neovascularization and subsequent fibrosis. To dem-
onstrate proof of the principle that CXC chemokines
regulate angiogenic and angiostatic activity in IPF, Keane
et al. effectively assessed the relevance of macrophage
inflammatory protein [61] and CXCL10 [62] with the aug-
mented net angiogenic activity in the in vivo model of
pulmonary fibrosis. Neutralization of (MIP)-2 attenuated
both angiogenic activity and the fibrotic response to bleo-
mycin, whereas a relative deficiency of IFN-γ inducible
angiostatic regulator CXCL10 was also noted. In addition,
systemic administration of CXCL10 inhibited fibroplasia
and angiogenesis, supporting the premise that aberrant
angiogenesis enhances fibroblast proliferation and ECM
deposition. In agreement with these findings, Burdick et
al. [63] stated that instillation of the angiostatic CXCL11
produced a marked decrease of fibrotic areas and an atten-
uation of the dysregulated vascular remodeling.
Fueled by the prospect that anti-angiogenic treatment
could be beneficial for pulmonary fibrosis, Hamada et al.
[64] tested the efficacy of anti-VEGF gene therapy in the
bleomycin model of pulmonary fibrosis. Administration
of a specific VEGF receptor that blocks its activity pro-
duced a significant anti-fibrotic, anti-inflammatory and
anti-angiogenic effect, suggesting an important role for
VEGF through its versatile properties. In addition, Jiang etRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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al. [65] used CXCR3 deficient mice and delineated poten-
tial mechanisms through which the CXCR3/CXCR3-lig-
ands biological axis exerts a protective role by shifting the
Th equilibrium toward resolution of the injurious
response. Moreover, Belperio et al. [52] by using a murine
model of bronchiolitis obliterans syndrome (BOS) con-
ducted a proof-of-concept analysis and demonstrated that
multiple angiogenic CXC chemokines and their receptors
(CXCR2) are involved in a dual fashion in the pathoge-
netic pathway of experimental BOS.
The latter results have clear therapeutic implications since
inhibition of angiogenic mediators or administration of
angiostatic chemokines reduced lung collagen deposition
and attenuated the exaggerated matrix remodeling. On
the basis of this concept, neutralization of proangiogenic
environment should be pursued. However, the latter
statement should be treated with caution for the follow-
ing reasons: 1) Findings derived from the bleomycin
model of pulmonary fibrosis may not be applicable to
human disease since pathogenetic components seen in
bleomycin-induced pulmonary fibrosis do not demon-
strate areas compatible with fibroblastic foci, the leading
edge of human fibrosis. In addition, there are clear limita-
tions to this model in terms of its self-limiting nature, the
rapidity of its development and the close association with
inflammation that accompanies the lung injury [66].
Regarding the experimental model of BOS, it also presents
with substantial weaknesses due to its heterotopic posi-
tioning, discounting the influence of adjacent airway
mucosa [52]. 2) Moreover, the aforementioned studies
were unable to investigate the complete angiogenic and
angiostatic network involved in the pathogenesis of the
disease. Therefore, results could be misleading due to the
lack of knowledge of a variety of mediators that may have
a direct effect on fibroblast proliferation and collagen
gene expression. Therefore, their potential contribution to
vascular and matrix remodeling can not be excluded.
Maybe an investigation of several angiogenic pathways in
a single experiment could help us circumvent this prob-
lem. However, the above limitations are not to diminish
the scientific value and accuracy of these studies but to
underline the necessity for further analyses using more
representative experimental models in combination with
human studies.
b. Angiogenesis in sarcoidosis (Table 5)
Recent immunological advances on sarcoidosis have
revealed a T helper 1 (Th1) and T helper 2 (Th2) paradigm
with predominance of the Th1 response in its immun-
opathogenesis [67,68]. The last years have seen the emer-
gence of Th1 mediators with pleiotropic properties
including the IFN-γ-regulated CXC chemokines that lack
the ELR motif (ELR-) at the NH2 terminus. While CXCR3/
CXCR3 ligands inhibit angiogenesis, CXCR3 ligands play
a pivotal role in orchestrating Th1 cytokine-induced cell-
mediated immunity via the recruitment of mononuclear
and CD4+ T-cells expressing CXCR3 and consequently via
Table 5: Studies investigating angiogenic and angiostatic parameters in patients with sarcoidosis
Investigator (year) Tissue samples Sample 
size
Studied Parameters Summary Limitations
Agostini et al. 69 (1998) Lung specimens/BALF 
samples/24 patients/6 
controls
CXCL10 Increased expression of 
CXCL10 in sarcoid tissues 
/ Positive relation of 
elevated CXCL10 BALF 
levels with T cell alveolitis
Lack of knowledge 
regarding regulators of 
CXCL10 expression / 
Incomplete analysis of the 
Th1 response / Small 
sample size
Miotto et al. 70 (2001) Lung specimens/BALF/ 39 
patients/10 controls
CXCL10, MCPs, eotaxin Increased expression of 
CXCL10 levels in 
sarcoidosis patients
Expression of CXCL10 not 
selective for Th1 mediated 
response / Lack of 
association with 
parameters of disease 
severity
Sekiya et al. 72 (2003) Serum samples/33 patients VEGF VEGF as a prognosticator 
of disease activity and 
extent
Retrospective analysis No 
serial measurement / No 
relation with serological 
parameters of disease 
severity / Limited number 
of patients
Katoh et al. 71 (2005) BALF and serum samples CXCL9, 10 Increased BALF 
concentrations in 
sarcoidosis patients
Discrepancies between 
BALF and serum levels / 
No relation with clinical 
parameters of disease 
severity
Abbreviations: BALF: Bronchoalveolar lavage fluid, MCPs: Monocyte chemotactic proteins, VEGF: Vascular endothelial growth factorRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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the granuloma formation (1). So far, there are only few
studies in the literature implicating angiogenesis in the
immunomodulatory cascade of sarcoidosis and correlat-
ing its immunopathogenesis with members of the angi-
ostatic group of CXC chemokines. These studies are
discussed in the following lines.
The concept of disparate activity of the IFN-γ-induced
CXC chemokines in the context of Th1-like immune dis-
orders, such as sarcoidosis, was originally raised by Agos-
tini et al. [69] who documented an enhanced expression
of IP-10 in sarcoid tissues and a positive relationship of
BALF IP-10 levels and the degree of T-cell alveolitis, sug-
gesting its pivotal role in ruling the migration of T-cells to
sites of ongoing inflammation. In addition, Miotto et al.
[70] described a specific for Th1 mediated response upreg-
ulation of IP-10 BALF levels further implicating angi-
ostatic CXC chemokines in the inflammatory cascade of
sarcoidosis. Recently, Katoh et al. [71] reported elevated
BALF concentrations of IP-10 and MIG in patients with
sarcoidosis and chronic eosinophilic pneumonia. Further-
more, Sekiya et al. [72] demonstrated a strong correlation
of elevated VEGF serum levels with clinical parameters of
disease activity and severity in sarcoidosis patients indicat-
ing a potential usefulness as a predictor of disease extent
and responsiveness to treatment.
The aforementioned studies substantiate the assertion
that IFN-γ-induced CXC chemokines are strongly involved
in the immunomodulatory cascade of sarcoidosis impli-
cating angiostasis with Th1 immune response. However,
there are several arguments that should be addressed. The
majority of the studies cited above have investigated the
ability of CXCR3 ligands to promote Th1-dependent
immunity and not to inhibit angiogenesis. Studies have
shown that angiostatic CXC chemokines are more likely
to contribute to the granuloma formation through their
chemotactic rather than angiostatic properties. The con-
tention of "immunoangiostasis" (promotion of Th1
response and at the same time inhibition of angiogenesis)
as it has been coined out by Strieter et al. [11] may possi-
bly support the infectious aetiology of sarcoidosis suggest-
ing that the hypovascular central area of the sarcoid
granuloma can contain the microbe in a dormant sate and
at the same time promote its eradication through Th1
mediating factors and the recruitment of T cells. There-
fore, it is tempting to speculate that factors that regulate
angiogenesis and promote aberrant vascular remodeling
can shift the Th1/Th2 equilibrium to Th2 immune
response resulting to fibrotic sarcoid phenotypes associ-
ated with detrimental prognosis and clinical course. How-
ever, there is major lack of knowledge regarding this issue.
Future analyses of the angiogenic microenvironment in
well defined subgroups of patients with sarcoidosis with
and without pulmonary fibrosis are warranted to eluci-
date the role of angiogenesis during this pathogenetic
process and support this concept.
Future challenges and limitations
IIPs are a heterogeneous group of diffuse parenchymal
disorders resulting from damage to the lung parenchyma
by varying patterns of inflammation and fibrosis. On the
other hand several patients with sarcoidosis develop irre-
versible lung damage and pulmonary fibrosis which cul-
minates to a fatal outcome. Several theories and
mechanisms have been delineated regarding the patho-
genesis of fibrotic lung disorders. Recent evidence support
the concept that inflammation is subsequent to injury and
that fibrosis occurs as a polarization of the Th2 immune
response of the body to repeated injury to the lung ("mul-
tiple hits" hypothesis) [9,73].
Putting the aforementioned data together, we tentatively
present the three current theories regarding the role of
aberrant vascular remodeling in the fibrogenic process.
The first hypothesis is based on the idea that the hypervas-
cularity observed in the least fibrotic areas has a role in the
regeneration of the alveolar septa damaged by the fibrotic
process and is a compensatory response to the decreased
vascularity seen within the fibroblastic foci (Figure 2). In
this case, the primary deficiency is the inability to form
new vessels in areas of extensive fibrosis and consequently
inhibition of angiogenesis could be detrimental [31].
Therefore the vascular ablation in areas proximal to gas
exchange may lead to an increased distance to be travelled
by oxygen and provide a plausible mechanism of the strik-
ing hypoxemia seen in end stage disease [28]. This is an
interesting theory; however, there is lack of evidence to
substantiate it. A comparative study of the HIF-1a-VEGF
axis in different areas of the same disease process or in dif-
ferent histopathologic patterns could be a possible
approach to this crucial issue. Potential disruption of this
pathway can explain the inability of lung to respond to
various stresses and injuries by the induction of VEGF
resulting to reduced endothelial and epithelial cell viabil-
ity that characterizes pulmonary fibrosis.
Alternative hypothesis regarding the role of vascular
remodeling during the process of ECM remodeling has
also emerged. This theory supports the premise that newly
formed microvessels enhance the exaggerated and dysreg-
ulated ECM deposition, support fibroproliferation and
inhibit normal epithelial repair mechanisms [50]. Human
[51,52] and animal [61-64] data has shown that inhibi-
tion of angiogenic mediators is followed by a significant
attenuation of the fibrotic process. Therefore it is tempting
to speculate that the increased angiogenic activity
observed in lung biopsies from patients with pulmonary
fibrosis facilitates the progression and expansion of the
fibrotic lesions in a similar way that promotes tumorRespiratory Research 2006, 7:82 http://respiratory-research.com/content/7/1/82
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growth and metastasis [74]. Turner-Warwick et al. [40]
originally demonstrated that the vascular supply of the
fibrotic regions derives from the systemic circulation
through systemic-pulmonary anastomoses. This observa-
tion correlates with the recently emerged theory of circu-
lating fibrocytes according to which bone marrow-derived
cells behave like mesenchymal stem cells and extravasate
into sites of tissue injury and contribute to pulmonary
fibrosis [9,75-77]. Hence, angiogenic cytokines in parallel
with their chemotactic properties may facilitate migration
of fibroblasts at areas of tissue injury by formation of new
blood vessels which may help to provide fibrotic regions
with the nutrient supplies needed for cellular prolifera-
tion and differentiation. However, findings from current
studies [50,53,54] question this hypothesis on the basis of
the striking hypovascularity within the areas of active
fibrosis. Nevertheless, the natural history of IIPs and espe-
cially IPF includes a series of overlapping events and is
characterized by a temporal and regional heterogeneity
[9]. Thereby, the finding of vascular heterogeneity is com-
patible and logical and supports the concept that angio-
genesis is a major or minor contributor of the fibrotic
process depending on the stage and the severity of the dis-
ease course. A longitudinal angiogenic study of biopsy
specimens from patients with fibrotic lung disease of dif-
ferent histopathologic patterns is crucial to elucidate the
role of vascular remodeling during different time points of
the disease course.
The third theory supports the notion that the role of ang-
iogenesis in the pathologic process of pulmonary fibrosis
is overestimated and that aberrant vascular remodeling is
just a bystander or a consequence of fibrogenesis. The lat-
ter idea is based on the assertion that CXC chemokines
may exert their anti-fibrotic activities through pathoge-
netic pathways different from those of angiogenesis [78].
The aforementioned observation coupled with major con-
troversies regarding the sequential pathologic events cul-
minating to pulmonary fibrosis give credence to the view
that angiogenesis is just a bystander or a consequence of
the fibrogenic process and is not actively involved in its
initiation and progression. Although, authors are not
strong supporters of this theory, however it should not be
excluded.
Based on the above data we can state that although several
study groups have investigated aberrant vascular remode-
ling in the pathogenesis of pulmonary fibrosis, the rela-
tive roles played by new vessel formation and vascular
regression in IPF and subsequently in other fibrotic lung
disorders are still elusive and controversial. However, to
address this issue further investigation in the context of
large prospective multicenter studies using highly stand-
ardized techniques is sorely needed. The emergence of
massive genome screening tools (DNA microarrays) [79]
coupled with reliable validation techniques (tissue micro-
arrays) [80] can help scientists to illuminate the interplay
between vascular and matrix remodeling in the pathogen-
esis of fibrotic ILDs and elevate its current state of knowl-
edge to the same level as for angiogenesis in tumor growth
and metastasis.
Conclusion
Several lines of research have been proven inadequate to
demystify the relative role of angiogenesis in the etio-
pathogenesis of chronic fibroproliferative disorders. The
question originally raised still remains unanswered: "A
pathogenetic hallmark of just a bystander?" However, the
status of knowledge regarding the contribution of newly
formed vessels in the initiation and/or progression of the
sequential events of abnormal injurious response, para-
doxical apoptosis and exaggerated matrix remodeling has
been greatly elevated by several studies. So far, a number
of investigations give credence to the view that a chemok-
ine imbalance favoring angiogenesis supports fibroprolif-
eration and inhibits normal repair mechanisms.
Alternatively, the regional vascular heterogeneity in IPF
can be explained as a compensatory response (vascular
regression) to the striking hypovascularity described in
areas of active fibrosis. Currently, angiogenesis represents
one of the most fruitful applications in the therapeutic
minefield of fibrotic lung disorders. The lack of an effec-
tive treatment option challenges chest physicians to think
beyond conventional therapeutic strategies and apply
fresh approaches. Blockage of multiple angiogenic media-
tors may provide a way forward. Whether our hopes will
be fulfilled or disproved remains to be seen.
Expression of angiogenic and angiostatic mediators within the  fibroblastic foci in UIP-IPF pattern Figure 2
Expression of angiogenic and angiostatic mediators within the 
fibroblastic foci in UIP-IPF pattern. Red arrows demonstrate 
the increased or decreased expression of angiogenic and 
angiostatic regulators within areas of active fibrosis.
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